Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

1d ago, source:

Abstract, OraGrowtH210 Trial (Phase 2): Oral LUM-201 Shows Similar Annualized Height Velocity to Daily rhGH in Moderate Pediatric Growth Hormone Deficiency (PGHD) with a 1.6mg/kg/day Dose and a ...

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

1mon ago, source: Business Insider

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript March 7, 2024 Lumos Pharma, Inc. isn't one of the 30 most ...

Lumos Pharma Inc LUMO

8d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Lumos Pharma FY 2023 Earnings Preview

on MSN ago, source:

Lumos Pharma, Inc. 2023 Q3 - Results - Earnings Call Presentation Lumos Pharma promotes Pisit Pitukcheewanont to chief ...

Lumos Pharma Stock (NASDAQ:LUMO), Analyst Ratings, Price Targets, Predictions

1mon ago, source: Benzinga.com

$2.78 871.22% HC Wainwright & Co.

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

1d ago, source: Stockhouse

CloseCurlyDoubleQuote; Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and ...

Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript

1mon ago, source: Seeking Alpha

Good afternoon and welcome to Lumos Pharma’s 2023 Fourth Quarter and Year End Conference Call. Currently all participants are on a listen-only mode. Later we will conduct a question-and-answer ...

Lumos Pharma Inc LUMO

26d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

1mon ago, source: WHNT

This press release contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this press release are forward ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

Lumos Pharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to Lumos Pharma’s 2023 ...

Lumos Pharma, Inc.: Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

1mon ago, source: Finanznachrichten

nasdaq 100 euro stoxx 50 ftse-100 ...